Visiongain has published a new report on Vaginitis Therapeutics Market Report 2021-2031: Forecasts by Product (Anti-fungal, Hormone, Anti-bacterial), By Type (OTC, Prescription). PLUS Profiles of Leading Pharma Contract Manufacturing Companies and Regional and Leading National Market Analysis. PLUS COVID-19 Recovery Scenarios.

Global Vaginitis Therapeutics market was valued at US$ xx billion in 2020 and is projected to reach at a market value of US$ xx billion by 2031.

Vaginitis is a frequently occurring medical disorder in women associated with substantial illness and formerly unnoticed complications. Extensive research in the past few years has led to the development of diagnostic tools as well as treatment modalities for all forms of vaginitis. Vaginitis is an infection of the vagina that can result in itching, discharge, and pain. "Yeast" infections, bacterial vaginosis, tyrichomoniasis vaginitis, chlamydia vaginitis, and viral vaginitis are the major forms of vaginitis. Around one third women across the world experience indications of vaginitis at some point in their lifetime. Women are highly susceptible to vaginitis during the reproductive age; a change in balance of bacteria and yeast present in vagina can result in vaginitis.

Market Drivers
Ongoing clinical trial conducted by many pharmaceuticals industries is propelling the growth of this market. Increase in use of antibiotics is likely to boost the market growth
High demand of disease specific novel treatment can also act as a market driver. The competitive scenario of market and strategic collaborations may boost the market position

Market Opportunities
Though hormonal treatment sub-segment is anticipated to observe the fastest growth over the coming years. Most of the hormonal treatments are easily reached only through prescription. The incidence of strong pipeline drugs is anticipated to support the segment for fastest growth during the forthcoming years.

Competitive Landscape
Global Vaginitis therapeutics market is highly fragmented and the major players have used various strategies such as new product launches, expansions, agreements, joint ventures, partnerships,acquisitions and others to increase their footprints in this market
Some companies are mentioned- Pfizer, Inc., Janssen Pharmaceuticals, Abbott Laboratories, GlaxoSmithKline plc, Sanofi, Novartis AG, Bayer AG, Bristol-Myers-Squibb Company, Eli Lilly and Company, Merck & Co. Inc., Astellas Pharma, Inc., Enzon Pharmaceuticals, Inc., Galderma SA, Gilead Sciences, Inc., Medicis Pharmaceutical Corp., Teva Pharmaceutical Industries, Ltd., and Starpharma Holdings Limited.

Most of these players are approving strategies, such as collaborations, new drug development, M&A, business expansion in emerging regions. For instance, in October 2017, Lupin Pharmaceuticals acquired Symbiomix Therapeutics to increase its product range. In October 2017, Pfizer Inc. pronounced the review of strategic alternative for spin off its Consumer Healthcare Business as a strategic initiative.

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongain.com or call her on +44 (0) 20 7549 9987.

About Visiongain
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.